On the recordMarch 7, 2012
Despite the success of Accelerated Approval for cancer drugs, I have talked with patients and innovators and investors, and they indicate that some in FDA intend to limit the use of the Accelerated Approval pathway for cancer drugs.
Source
congress.gov




